The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 356:2003 May 10, 2007 Number 19
NextNext

Interleukin-12/23 Monoclonal Antibody for Psoriasis

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Lautrette, A.
-Related Article
by Krueger, G. G.
-PubMed Citation
To the Editor: In a double-blind, placebo-controlled trial, Krueger et al. (Feb. 8 issue)1 show that an interleukin-12/23 monoclonal antibody is an effective treatment for psoriasis. The production of aberrant helper T-cell type 1 cytokines, including interleukin-12 and interleukin-23, has long been considered to play an important role in the pathogenesis of psoriasis. Psoriatic arthritis is an extradermal manifestation of psoriasis, and type 1 cytokines have pathologic roles in rheumatoid arthritis. In the study by Krueger et al., each of the five groups included 12 patients (19%) or 13 patients (20%) with psoriatic arthritis. In view of the roles that . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.